Mazetol SR 300 Tablet contains Carbamazepine 300 mg, an anticonvulsant and mood-stabilizing agent primarily indicated for the management of epilepsy, trigeminal neuralgia, and bipolar disorder. Carbamazepine acts by stabilizing the inactivated state of voltage-gated sodium channels, thereby reducing neuronal excitability and preventing the propagation of abnormal electrical discharges in the brain. Mazetol SR 300 is formulated as a sustained-release tablet to provide a controlled and prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. It is effective in controlling partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizure types. Additionally, it is utilized in the treatment of neuropathic pain and certain psychiatric conditions due to its mood-stabilizing properties. The medication should be administered under medical supervision, with careful dose titration to minimize adverse effects such as dizziness, drowsiness, nausea, and potential hematologic abnormalities. Regular monitoring of liver function, blood counts, and serum drug levels is recommended to ensure safety and efficacy. Mazetol SR 300 should be used cautiously in patients with a history of bone marrow suppression, cardiac conduction disorders, or hypersensitivity to carbamazepine or related compounds. It is contraindicated during pregnancy unless the benefits outweigh the risks.